February 10, 2023 - C/A: Amendment to Offering statement

Issuer Information

Name of Issuer:

FibroBiologics, Inc.

Check box if Amendment is material and investors will have five business days to reconfirm

Describe the Nature of the Amendment:

Updated clerical error with perk language

Legal Status of Issuer:

Form:

Corporation

Jurisdiction of Incorporation/Organization:

DELAWARE

Date of Incorporation/Organization:

04-08-2021

Physical Address of Issuer:

Address 1:

455 E. Medical Center Blvd, Suite 300

City:

Houston

State/Country:

TEXAS

Mailing Zip/Postal Code:

77598

Website of Issuer:

https://fibrobiologics.com/

Is there a Co-issuer?

Yes

No

Intermediary through which the Offering will be Conducted:

CIK:

0001665160

Company Name:

StartEngine Capital, LLC

Commission File Number:

007-00007

Offering Information

Amount of compensation to be paid to the intermediary, whether as a dollar amount or a percentage of the offering amount, or a good faith estimate if the exact amount is not available at the time of the filing, for conducting the offering, including the amount of referral and any other fees associated with the offering:

up to 9% percent

Any other financial interest in the issuer held by the intermediary, or any arrangement for the intermediary to acquire such an interest:

Three percent (3%) of securities of the total amount of investments raised in the offering, along the same terms as investors.

Type of Security Offered:

Other

Specify:

Series B Preferred Stock

Target Number of Securities to be Offered:

5917

Price:

1.69000

Price (or Method for Determining Price):

N/A

Target Offering Amount:

9999.73

Maximum Offering Amount (if different from Target Offering Amount):

4999998.51

Oversubscriptions Accepted:

Yes

No

If yes, disclose how oversubscriptions will be allocated:

Other

Provide a description:

At issuer's discretion, with priority given to StartEngine Owners

Deadline to reach the Target Offering Amount:

05-01-2023

NOTE: If the sum of the investment commitments does not equal or exceed the target offering amount at the offering deadline, no securities will be sold in the offering, investment commitments will be cancelled and committed funds will be returned.

Annual Report Disclosure Requirements

Current Number of Employees:

5

Total Assets Most Recent Fiscal Year-end:

468000.00

Total Assets Prior Fiscal Year-end:

0.00

Cash and Cash Equivalents Most Recent Fiscal Year-end:

407000.00

Cash and Cash Equivalents Prior Fiscal Year-end:

0.00

Accounts Receivable Most Recent Fiscal Year-end:

0.00

Accounts Receivable Prior Fiscal Year-end:

0.00

Short-term Debt Most Recent Fiscal Year-end:

1758000.00

Short-term Debt Prior Fiscal Year-end:

0.00

Long-term Debt Most Recent Fiscal Year-end:

0.00

Long-term Debt Prior Fiscal Year-end:

0.00

Revenue/Sales Most Recent Fiscal Year-end:

0.00

Revenue/Sales Prior Fiscal Year-end:

0.00

Cost of Goods Sold Most Recent Fiscal Year-end:

0.00

Cost of Goods Sold Prior Fiscal Year-end:

0.00

Taxes Paid Most Recent Fiscal Year-end:

0.00

Taxes Paid Prior Fiscal Year-end:

0.00

Net Income Most Recent Fiscal Year-end:

-1582000.00

Net Income Prior Fiscal Year-end:

-1169000.00